However, a metastasis suppressor role of NME2 has been demonstrated in BCa, lung cancer, oral squamous carcinoma, melanoma, gastric cancer, endometrial cancer, HCC, thyroid carcinoma, and osteosarcoma. This evidence concerns the gene NME2 and hepatocellular carcinoma.